Neurofibromatosis
With Jill Knepprath
Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Answers come only from this collection's statement ledger and cite the exact moment · not medical advice
Content of this collection
Evidence & Research
1 item
Malignant peripheral nerve sheath tumors: a report from Children’s Oncology Group study ARST0332
Watch →
Jacquelyn N Crane, Wei Xue, Amira Qumseya, Donald A Barkauskas, Khang Chau, Serena Y Tan, Susan Hiniker, Roshni Dasgupta, Rajkumar Venkatramani, Sheri L Spunt, Aaron R Weiss, Theodore W LaetschBackground: The cornerstone of the treatment of
video · 1:11 · Mar 2026
Share & build on it
Want more on this topic?+ Show
The story of this collection+ Show
Featured chapters & key critical points+ Show
Featured picks for families are being prepared — the summaries above are written for you.
What we know now+ Show
The doctors+ Show
Inside the topic+ Show
Every statement below comes from the recorded discussions, with its speaker and moment.
Malignant peripheral nerve sheath tumors: a report from Children’s Oncology Group study ARST0332
The Children's Oncology Group published a prospective trial on malignant peripheral nerve sheath tumors in the Journal of the National Cancer Institute in 2025.
clinicalJill Knepprath0:11 ↗
Patients were assigned to four treatment groups: observation, adjuvant radiation, adjuvant chemoradiation, and neoadjuvant chemoradiation.
clinicalJill Knepprath0:24 ↗
Resection has a major influence on survival for patients with malignant peripheral nerve sheath tumors.
clinicalJill Knepprath0:35 ↗
Female patients with malignant peripheral nerve sheath tumors had improved outcomes.
epidemiologicalJill Knepprath0:40 ↗
Patients without metastatic disease had improved outcomes.
clinicalJill Knepprath0:40 ↗
Low-risk patients had improved outcomes.
clinicalJill Knepprath0:40 ↗
In patients receiving neoadjuvant therapy, 23% showed a response.
clinicalJill Knepprath0:46 ↗
In patients receiving neoadjuvant therapy, 45% were stable.
clinicalJill Knepprath0:46 ↗
In patients receiving neoadjuvant therapy, 32% had progressive disease.
clinicalJill Knepprath0:46 ↗
There was no difference in survival based on the response to neoadjuvant therapy among patients who went on to have resection.
clinicalJill Knepprath0:59 ↗
Resection should be done for patients with malignant peripheral nerve sheath tumors whenever possible, even if they show a good response to chemoradiation.
guidelineJill Knepprath1:03 ↗